Angelica sinensis polysaccharide combined with cisplatin reverses cisplatin resistance of ovarian cancer by inducing ferroptosis via regulating GPX4 - 29/05/24

Abstract |
Cisplatin (DDP) resistance poses a significant challenge in the treatment of ovarian cancer. Studies have shown that the combination of certain polysaccharides derived from plants with DDP is an effective approach to overcoming drug resistance in some cancers. Angelica sinensis (Oliv.) Diels has been used for centuries in China to treat gynecological ailments. Numerous studies indicate that Angelica sinensis polysaccharide (ASP), an extract from Angelica sinensis, can inhibit various forms of cancer. However, the impact of ASP on ovarian cancer remains unexplored. Through both in vitro and in vivo experiments, our study revealed the capability of ASP to effectively reversing DDP resistance in cisplatin-resistant ovarian cancer cells, while exhibiting acceptable safety profiles in vivo. To elucidate the mechanism underlying drug resistance reversal, we employed RNA-seq analysis and identified GPX4 as a key gene. Considering the role of GPX4 in ferroptosis, we conducted additional research to explore the effects of combining ASP with DDP on SKOV3/DDP cells. In summary, our findings demonstrate that the combination of ASP and DDP effectively suppresses GPX4 expression in SKOV3/DDP cells, thereby reversing their resistance to DDP.
Le texte complet de cet article est disponible en PDF.Graphical Abstract |
Highlights |
• | ASP combined with DDP can inhibit the proliferation and invasion of cisplatin-resistant ovarian cancer cells and promote their apoptosis. |
• | ASP combined with DDP can inhibit cisplatin-resistant ovarian cancer cells proliferation in vivo. |
• | ASP combined with DDP can inhibit GPX4 expression and promote ferroptosis in cisplatin-resistant ovarian cancer cells. |
• | ASP can reverse the resistance of cisplatin-resistant ovarian cancer cells to DDP. |
Keywords : Ovarian cancer, Angelica sinensis polysaccharide (ASP), GPX4, Ferroptosis, Cisplatin resistance
Plan
Vol 175
Article 116680- juin 2024 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
